HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – 1% Chloroprocaine(PF) vs. Bupivacaine Spinals
The use of 1% Chloroprocaine (PF) spinal anesthesia will reduce the recovery times and
discharge time of patients undergoing hemorrhoidectomies as compared to 0.75% bupivacaine
spinal. The primary objective is to compare the recovery times (return of motor and sensory
function) and discharge time (voiding time) between 2-Chloroprocaine and 0.75% bupivacaine
spinal anesthesia for hemorrhoidectomies. This is a randomized, prospective study assigning
patients to either 2-Chloroprocaine (PF) or 0.75% bupivacaine spinal anesthesia group.
Clinical Trial – RCT of Epinephrine (None, 100mcg, and 200mcg) in a Hyperbaric Bupivacaine, Fentanyl and Morphine Spinal in C-sections.
This is a prospective, randomized, double blind study of 75 patients (n=25 for each group) in
which epinephrine (100mcg or 200mcg) or normal saline vehicle is added to intrathecal
hyperbaric bupivacaine (0.75% bupivacaine hydrochloride in 8.25% dextrose), fentanyl, and
morphine to prolong the duration of the spinal anesthetic in scheduled cesarean deliveries.
The primary outcome of duration will be the time to T10 level sensory regression as well as
motor level regression that will be graded via the modified Bromage scale.
Repeat cesarean sections, in particular, are associated with increased operative time and
thus often performed with a spinal-epidural (CSE) technique. The epidural component is,
however, untested and may not provide adequate anesthesia, thus the higher risk of conversion
to a general anesthesia. Epinephrine is routinely used to prolong spinal anesthesia. If
effective for the duration of a repeat cesarean section it would obviate the additional time
and risks of performing the epidural and still avoid sufficient duration to avoid conversion
to a general anesthetic.
Current treatment of central retinal artery occlusion: a national survey.
Central retinal artery occlusion (CRAO) is an ophthalmological emergency, the retinal analog of a stroke. To date there is no consensus or national guidelines on how this disorder should be managed. As academic neurologists and ophthalmologists treat CRAO frequently, we set out to understand how these clinicians approach patients with CRAO with a national survey. We identified university-associated teaching hospitals offering vascular neurology, neuro-ophthalmology and/or retina fellowships in the US and asked the directors of the programs to respond to questions in an open response format to profile the acute management of CRAO at their institution.